Sofie Taageby Nielsen

Sofie Taageby Nielsen

Auto-generated profile, based on publicly available information

Sofie Taageby Nielsen

Department of Clinical Biochemistry, Copenhagen University Hospital—Rigshospitalet , Blegdamsvej 9, DK-2100 Copenhagen

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2023 in European Heart Journal
Verified
Journal Article
Open access
PDF file
SNSofie Taageby Nielsen
Sofie Taageby Nielsen
RLRikke Mohr Lytsen
Rikke Mohr Lytsen
NSNina Strandkjær
Nina Strandkjær
IRIda Juul Rasmussen
Ida Juul Rasmussen
ASAnne-Sophie Sillesen
Anne-Sophie Sillesen
RFRuth Frikke-Schmidt
Ruth Frikke-Schmidt
Background and Aims: The aims of this study were to investigate lipid parameters during the first 14–16 months of life, to identify influential factors, and to test whether high concentrations at birth predict high concentrations at 2- and 14–16 months. Methods: The Copenhagen Baby Heart Study, including 13,354 umbilical cord blood samples and parallel venous blood samples from children and parents at birth (n = 444), 2 months (n = 364), and 14–16 months (n = 168), was used. Results: Concentrations of lipids, lipoproteins, and apolipoproteins in umbilical cord blood samples correlated highly with venous blood samples from newborns. Concentrations of low-density lipoprotein (LDL) cholesterol, non-high-density lipoprotein (HDL) cholesterol, apolipoprotein B, and lipoprotein(a) increased stepwise from birth to 2 months to 14–16 months. Linear mixed models showed that concentrations of LDL cholesterol, non-HDL cholesterol, and lipoprotein(a) above the 80th percentile at birth were associated with significantly higher concentrations at 2 and 14–16 months. Finally, lipid concentrations differed according to sex, gestational age, birth weight, breastfeeding, and parental lipid concentrations. Conclusions: Lipid parameters changed during the first 14–16 months of life, and sex, gestational age, birth weight, breastfeeding, and high parental concentrations influenced concentrations. Children with high concentrations of atherogenic lipid traits at birth had higher concentrations at 2 and 14–16 months. These findings increase our knowledge of how lipid traits develop over the first 14–16 months of life and may help in deciding the optimal child age for universal familial hypercholesterolaemia screening.

3 September 2025 in European Heart Journal
Verified
Journal Article
Open access
SNSofie Taageby Nielsen
Sofie Taageby Nielsen
JLJIAO LUO
JIAO LUO
ATAnne Tybjærg-Hansen
Anne Tybjærg-Hansen
KIKasper Iversen
Kasper Iversen
HBHenning Bundgaard
Henning Bundgaard
RFRuth Frikke-Schmidt
Ruth Frikke-Schmidt
Background and Aims: Observational studies show that women with hypertensive disorders of pregnancy have greater risk of cardiovascular disease later in life. Whether these associations reflect causal pathways is uncertain. This study used genetic epidemiology to explore the causal relevance of preeclampsia and gestational hypertension on cardiovascular disease. Methods: Two-sample Mendelian randomization (MR) analyses were conducted using summary-level data from FinnGen and from the to date largest consortia for each outcome. One-sample MR analyses were performed using individual-level data from 202 876 White British women from the UK Biobank. Genetic instruments for preeclampsia and gestational hypertension were from the most updated genome-wide association study (n = 20 064 preeclampsia cases; n = 703 117 controls; n = 11 027 gestational hypertension cases; n = 412 788 controls). Results: In two-sample MR analyses, higher genetic predisposition to preeclampsia was associated with greater risk of ischaemic heart disease [odds ratio 1.20 (95% confidence interval 1.06–1.35)], myocardial infarction [1.29 (1.13–1.47)], stroke [1.23 (1.12–1.35)], ischaemic stroke [1.21 (1.10–1.33)], atrial fibrillation [1.13 (1.01–1.25)], and heart failure [1.11 (1.04–1.20)]. For higher genetic predisposition to gestational hypertension, corresponding odds ratios were 1.21 (1.10–1.33), 1.26 (1.16–1.36), 1.30 (1.23–1.37), 1.24 (1.17–1.32), 1.29 (1.17–1.42), and 1.09 (1.03–1.15). The MR-Egger results did not suggest pleiotropy. One-sample analyses were broadly consistent with the main findings. Conclusions: Genetic predisposition to hypertensive disorders of pregnancy was associated with greater risk of cardiovascular disease later in life, highlighting the importance of enhanced cardiovascular surveillance in this population.

23 October 2025 in European Heart Journal
Verified
Journal Article
Closed access
SNSofie Taageby Nielsen
Sofie Taageby Nielsen
RFRuth Frikke-Schmidt
Ruth Frikke-Schmidt

25 November 2025 in European Heart Journal
Verified
Journal Article
Closed access
SNSofie Taageby Nielsen
Sofie Taageby Nielsen
JLJIAO LUO
JIAO LUO
RFRuth Frikke-Schmidt
Ruth Frikke-Schmidt

12 June 2026 in Cardiovascular Research
Verified
Journal Article
Closed access
RLRikke Mohr Lytsen
Rikke Mohr Lytsen
SNSofie Taageby Nielsen
Sofie Taageby Nielsen
NSNina Strandkjær
Nina Strandkjær
IRIda Juul Rasmussen
Ida Juul Rasmussen
ASAnne-Sophie Sillesen
Anne-Sophie Sillesen
RFRuth Frikke-Schmidt
Ruth Frikke-Schmidt
Aims: Foetal cholesterol is primarily carried by high-density lipoprotein (HDL) enriched with apolipoprotein E (apoE) and the foetus depends on a maternal-placental supply in early gestation until foetal de novo synthesis is established. We aimed to examine HDL cholesterol (HDL-C), apoE, and apolipoprotein AI (apoAI) concentrations in early life and the association with foetal growth and placental insufficiency. Methods and results: We used data from the Copenhagen Baby Heart and COMPARE study cohorts, including cord- (n = 13 353) and parallel child and maternal venous blood samples at birth (n = 444), 2- (n = 364), and 14–16 months (n = 156) after birth. HDL-C, apoAI, and apoE concentrations were higher in female vs. male newborns (P < 0.001). During the first 14–16 months of life, concentrations of HDL-C and apoAI increased (P < 0.02), apoE decreased (P < 0.001), and the HDL-C–apoAI correlation increased (Spearman's rho: 0.71, 0.87, 0.90), while the HDL-C–apoE correlation decreased (Spearman's rho: 0.58, 0.18). Small (SGA), appropriate (AGA), and large (LGA) for gestational age showed a stepwise increase in cord blood concentrations of HDL-C and apoE, but not apoA1, from SGA to LGA (P < 0.001). We found higher risk of low cord blood concentrations (<20th percentile) of HDL-C and apoE associated with placental insufficiency [odds ratio 1.39 (95% confidence interval 1.16–1.65) and 1.46 (1.22–1.75)], low pregnancy-associated plasma protein A (PAPP-A) [1.82 (1.47–2.25) and 1.50 (1.19–1.88)), preeclampsia (1.62 (1.28–2.04) and 1.39 (1.09–1.78)], hypertension (1.35 (1.05–1.73) and 1.28 (0.99–1.67)), body mass index (BMI) ≥ 25 kg/m2 [1.29 (1.17–1.43) and 1.13 (1.02–1.25)], and smoking [1.79 (1.43–2.23) and 1.38 (1.09–1.76)]. Only placental insufficiency [1.23 (1.03–1.48)], low PAPP-A [1.48 (1.18–1.85)], and smoking[(1.35 (1.06–1.72)] were associated with low cord blood apoAI. Conclusion: During the first 14–16 months of life, the apolipoprotein profile of HDL approaches that of adults. Offspring concentrations of HDL-C and apoE at birth were positively associated with foetal growth and placental insufficiency was associated with increased risk of low HDL-C and apoE, suggesting these traits as markers of placental function.